8-K: Hoth Therapeutics Faces Nasdaq Delisting Warning Due to Low Stock Price

Hoth Therapeutics has received a notification from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share for continued listing.

Summary

• Hoth Therapeutics received a notification from Nasdaq on May 13, 2025, stating that it is not in compliance with the minimum bid price requirement of $1.00 per share, as per Nasdaq Listing Rule 5550(a)(2).
• The deficiency period spanned from March 31, 2025, to May 12, 2025.
• The notification does not immediately affect the listing or trading of Hoth Therapeutics' common stock, which will continue to trade on The Nasdaq Capital Market under the symbol HOTH.
• Hoth Therapeutics has been granted a 180-day period, until November 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
• If compliance is not achieved by November 10, 2025, an additional 180 days may be granted if the company meets other Nasdaq Capital Market continued listing requirements and notifies Nasdaq of its intention to cure the deficiency.
• If the company fails to regain compliance within the allotted time, Nasdaq will proceed with delisting, which the company can appeal.
• Hoth Therapeutics intends to monitor its stock price and may consider options such as a reverse stock split to regain compliance.

Sentiment

Score: 4

Explanation: The news is negative as it indicates financial distress and potential delisting, but the company has time to rectify the situation.

Positives

• The notification does not immediately affect the listing or trading of Hoth Therapeutics' common stock.
• Hoth Therapeutics has been granted a 180-day period to regain compliance.
• An additional 180 days may be granted if certain conditions are met.
• The company can appeal any delisting determination.

Negatives

• Hoth Therapeutics is not in compliance with Nasdaq's minimum bid price requirement.
• The company's stock price has been below $1.00 for a sustained period.
• Failure to regain compliance could lead to delisting from The Nasdaq Capital Market.

Risks

• The company faces the risk of delisting from The Nasdaq Capital Market if it fails to regain compliance with the minimum bid price requirement.
• Implementing a reverse stock split may not guarantee long-term compliance and could negatively impact shareholder value.
• Market conditions and investor sentiment could hinder the company's ability to increase its stock price.

Future Outlook

Hoth Therapeutics intends to monitor its stock price and may consider implementing available options, including a reverse stock split, to regain compliance with Nasdaq Listing Rules.

Management Comments

• The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

Industry Context

Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance due to stock price volatility and market sentiment. This notification is not uncommon in the sector.

Comparison to Industry Standards

• Other biotech companies like 'Baudax Bio' and 'Therapix Biosciences' have faced similar delisting warnings from Nasdaq due to low stock prices.
• Companies often explore options like reverse stock splits, similar to what 'Hoth Therapeutics' is considering, to regain compliance, as seen with 'Aeterna Zentaris' in the past.
• The success of these strategies varies, and depends on the company's underlying financial health and market perception, as demonstrated by the differing outcomes of companies like 'Citius Pharmaceuticals' and 'Cyclacel Pharmaceuticals' after implementing reverse stock splits.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security.
• The company's reputation and ability to attract future investment could be negatively impacted.

Next Steps

• Hoth Therapeutics will monitor its stock price.
• The company may consider a reverse stock split.
• Hoth Therapeutics must regain compliance with Nasdaq Listing Rule 5550(a)(2) by November 10, 2025.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, compliance, Hoth Therapeutics, stock price, reverse stock split